Rps2, CPTAC-3872 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

non-CPTAC-6122: View additional GTGIVSAPVPK data

non-CPTAC-3872: View additional EVATAIR data

10 20 30 40 50
MADDAGAAGG PGGPGGPGLG GRGGFRGGFG SGLRGRGRGR GRGRGRGRGA
60 70 80 90 100
RGGKAEDKEW IPVTKLGRLV KDMKIKSLEE IYLFSLPIKE SEIIDFFLGA
110 120 130 140 150
SLKDEVLKIM PVQKQTRAGQ RTRFKAFVAI GDYNGHVGLG VKCSKEVATA
160 170 180 190 200
IRGAIILAKL SIVPVRRGYW GNKIGKPHTV PCKVTGRCGS VLVRLIPAPR
210 220 230 240 250
GTGIVSAPVP KKLLMMAGID DCYTSARGCT ATLGNFAKAT FDAISKTYSY
260 270 280 290 293
LTPDLWKETV FTKSPYQEFT DHLVKTHTRV SVQRTQAPAV ATT

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader


Assay Details for non-CPTAC-6122 Collapse assay details

Data source: Panorama

Official Gene Symbol

RPS2

Peptide Sequence

GTGIVSAPVPK

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

201

Peptide End

211

CPTAC ID

non-CPTAC-6122

Peptide Molecular Mass

1,024.5917

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

Bovine Serum Albumin

Submitting Laboratory

McGill University

Submitting Lab PI

Christoph H. Borchers, Gerald Batist


Publication

View Details (opens in a new window)

mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours. Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, Rene P Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

Agilent 6495B QQQ-MS

Internal Standard

Standard Isotope labeled internal standard peptides with 13Cx, 15Ny (R+10 or K+8)

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C and 15N at C-terminus K

LC

Infinity 1290

Column Packing

commercial (Agilent ZORBAX Eclipse Plus C18)

Column Dimensions

4.6 mm × 150 mm, (5 µm)

Flow Rate

0.4 mL/min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | b4 (1+) | 7.4 | 5.8 | 5.1 | 6.7 | 6.2 | 6.5 | 10 | 8.5 | 8.3 | 16 | 16 | 17 | | y2 (1+) | 8.9 | 5 | 6 | 9.7 | 7.4 | 5.3 | 13.2 | 8.9 | 8 | 16 | 16 | 17 | | y6 (1+) | 6.9 | 2.5 | 6.2 | 7.9 | 2.9 | 6 | 10.5 | 3.8 | 8.6 | 16 | 16 | 17 | | y7 (1+) | 9.7 | 5.6 | 5.2 | 10.6 | 5.5 | 5.3 | 14.4 | 7.8 | 7.4 | 16 | 16 | 17 | | y9 (1+) | 10 | 4.4 | 5.8 | 11.4 | 4.8 | 5.2 | 15.2 | 6.5 | 7.8 | 16 | 16 | 17 | | sum | 4.6 | 2.8 | 2.4 | 4.8 | 3 | 1.9 | 6.6 | 4.1 | 3.1 | 16 | 16 | 17 |



Additional Resources and Comments


Assay Details for non-CPTAC-3872 Collapse assay details

Data source: Panorama

Official Gene Symbol

Rps2

Peptide Sequence

EVATAIR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

146

Peptide End

152

CPTAC ID

non-CPTAC-3872

Peptide Molecular Mass

758.4287

Species

Mus musculus (Mouse)

Assay Type

Direct MRM

Matrix

Plasma

Submitting Laboratory

UVic-Genome BC Proteomics Centre

Submitting Lab PI

Christoph Borchers


Publication

View Details (opens in a new window)

Molecular phenotyping of laboratory mouse strains using 500 multiple reaction monitoring mass spectrometry plasma assays. Michaud SA, Sinclair NJ, Petrošová H, Palmer AL, Pistawka AJ, Zhang S, Hardie DB, Mohammed Y Eshghi A1, Richard VR, Sickmann A, Borchers CH. Commun Biol. 2018 Jun 27;1:78. doi: 10.1038/s42003-018-0087-6. eCollection 2018.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

Agilent 6490/6495 QQQ

Internal Standard

synthetic peptide

Peptide Standard Purity

>80%

Peptide Standard Label Type

13C and 15N at C-terminus R

LC

1290 LC (Agilent)

Column Packing

Zorbax Eclipse Plus C18, 1.8 µm

Column Dimensions

2.1 x 150 mm

Flow Rate

400 µL/min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | b4 (2+) | 8.2 | 4.7 | 5.3 | 13.5 | 6 | 6 | 15.8 | 7.6 | 8 | 15 | 15 | 15 | | y5 (2+) | 8.1 | 6 | 6.3 | 11.9 | 7.8 | 7.5 | 14.4 | 9.8 | 9.8 | 15 | 15 | 15 | | y3 (1+) | 8.3 | 6 | 3.7 | 8.3 | 7.5 | 8.9 | 11.7 | 9.6 | 9.6 | 15 | 15 | 15 | | y4 (1+) | 8 | 4.7 | 2.7 | 9.4 | 6.2 | 5.4 | 12.3 | 7.8 | 6 | 15 | 15 | 15 | | y5 (1+) | 6.9 | 5.1 | 5.1 | 5.9 | 7.8 | 8.4 | 9.1 | 9.3 | 9.8 | 15 | 15 | 15 | | sum | 3.2 | 2 | 3.2 | 5.4 | 5.4 | 6.4 | 6.3 | 5.8 | 7.2 | 15 | 15 | 15 |



Additional Resources and Comments